Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.51 |
| ▸ | G6PD | P11413 | 1/20 | 0.51 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7704782 | 0.81 | GLO1 (0.51) | GLO1ALOX15HTTTDP1POLB | |
| SCHEMBL4546341 | 0.79 | TDP1 (0.62) | GLO1ALOX15HTTTDP1POLB | |
| SCHEMBL379216 | 0.78 | GLO1 (0.59) | GLO1ALOX15HTTTDP1POLB | |
| SCHEMBL3156796 | 0.78 | MAPT (0.63) | GLO1ALOX15HTTTDP1POLB | |
| Hydrochloric Acid SCHEMBL28172351 | 0.77 | TDP1 (0.60) | GLO1ALOX15HTTTDP1POLB | |
| SCHEMBL7774451 | 0.75 | CYP3A4 (0.61) | GLO1ALOX15HTTTDP1POLB | |
| SCHEMBL31130165 | 0.75 | CYP3A4 (0.61) | GLO1ALOX15HTTTDP1POLB | |
| SCHEMBL17749155 | 0.75 | GLO1 (0.56) | GLO1ALOX15HTTTDP1POLB | |
| SCHEMBL13337941 | 0.75 | MEN1 (0.56) | GLO1ALOX15HTTTDP1POLB | |
| SCHEMBL27938447 | 0.75 | HTT (0.56) | GLO1ALOX15HTTTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743061-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | Pascal Biosciences Inc. (CA) | 2020-12-02 | — | — | EP | claimed |
| WO-2019144126-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2019-07-25 | — | — | WO | claimed |
| US-5633364-A | N4 -substituted 2'-deoxycytidine compounds, oligonucleotides including N4 -labeled 2'-deoxycytidines, and a process for making oligonucleotides with N-modified 2'-deoxycytidines | AMOCO CORPORATION (US) | 1997-05-27 | — | — | US | claimed |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
| WO-2022006498-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC. (CA) | 2022-01-06 | — | — | WO | disclosed |
| US-20210038559-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2021-02-11 | — | — | US | disclosed |
| EP-3743061-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | Pascal Biosciences Inc. (CA) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019144126-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2019-07-25 | — | — | WO | disclosed |
| CN-104220065-A | Substituted prolines/piperidines as orexin receptor antagonists | EOLAS THERAPEUTICS INC | 2014-12-17 | — | — | CN | disclosed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-5633364-A | N4 -substituted 2'-deoxycytidine compounds, oligonucleotides including N4 -labeled 2'-deoxycytidines, and a process for making oligonucleotides with N-modified 2'-deoxycytidines | AMOCO CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| US-5405950-A | N4 -substituted cytidines and process for incorporation into an oligonucleotides | AMOCO CORPORATION (US) | 1995-04-11 | — | — | US | disclosed |
| EP-0518961-A1 | DERIVATIVES OF GLYCINAMIDE, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | GLO1 3715/4885ALOX15 1124/4885HTT 2961/4885 |
| US-20210038559-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | CNR1, CNR2, CD74 | GLO1 2984/4885ALOX15 881/4885HTT 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.